<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01160</drugbank-id>
  <drugbank-id>APRD00926</drugbank-id>
  <name>Dinoprost tromethamine</name>
  <description>The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.</description>
  <cas-number>38562-01-5</cas-number>
  <unii>CT6BBQ5A68</unii>
  <average-mass>475.616</average-mass>
  <monoisotopic-mass>475.314517421</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Morozowich, W.; U.S. Patent 3,657,327; April 18,1972; assigned to The Upjohn Company.</synthesis-reference>
  <indication>Used for aborting second-trimester pregnancy (between the twelfth to eighteenth week of gestation) and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life. Also used at low-doses for medically indicated induction of labor at term. Also injected intra-arterially for use as a vasodilator to assist in angiography.</indication>
  <pharmacodynamics>Dinoprost tromethamine is the tromethamine (THAM) salt of the naturally occurring prostaglandin F2&lt;sub&gt;alpha&lt;/sub&gt;. Prostaglandin F2&lt;sub&gt;alpha&lt;/sub&gt;&amp;nbsp;has several pharmacologic effects on the female reproductive system, including stimulation of myometrial activity, relaxation of the cervix, inhibition of steroidogenesis by corpora lutea, and can potentially lyse corpora lutea.</pharmacodynamics>
  <mechanism-of-action>Dinoprost tromethamine appears to act directly on the myometrium, but this has not been completely established. Dinoprost stimulates myometrial contractions (via its interaction with the prostaglandin receptors) in the gravid uterus that are similar to the contractions that occur in the term uterus during labor. These contractions are usually sufficient to cause abortion. Uterine response to prostaglandins increases gradually throughout pregnancy. Dinoprost also facilitates cervical dilatation and softening.</mechanism-of-action>
  <toxicity>Although overdose by intra-amniotic administration of dinoprost has not been reported, exaggeration of the nausea, vomiting, and diarrhea that occur with normal doses would be expected.</toxicity>
  <metabolism>Enzymatic dehydrogenation primarily in the maternal lungs and also in the liver.</metabolism>
  <absorption>Slowly absorbed from the amniotic fluid into systemic circulation.</absorption>
  <half-life>The half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.</description>
    <direct-parent>Prostaglandins and related compounds</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Fatty Acyls</class>
    <subclass>Eicosanoids</subclass>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Cyclopentanols</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydroxy fatty acids</alternative-parent>
    <alternative-parent>Long-chain fatty acids</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Unsaturated fatty acids</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homomonocyclic compound</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Cyclopentanol</substituent>
    <substituent>Fatty acid</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydroxy fatty acid</substituent>
    <substituent>Long-chain fatty acid</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Prostaglandin skeleton</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Unsaturated fatty acid</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Dinoprost trometamol</synonym>
    <synonym language="english" coder="">PGF2-alpha THAM</synonym>
    <synonym language="english" coder="">PGF2A THAM</synonym>
    <synonym language="english" coder="">PGF2alpha THAM</synonym>
    <synonym language="english" coder="">Prostaglandin F2-alpha THAM</synonym>
    <synonym language="english" coder="">Prostaglandin F2a tromethamine</synonym>
    <synonym language="english" coder="">Prostaglandin F2alpha tham</synonym>
    <synonym language="english" coder="">Prostin F2 Alpha</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Dinolytic</name>
      <company>Pfizer</company>
    </international-brand>
    <international-brand>
      <name>Enzaprost F</name>
      <company>Chinoin</company>
    </international-brand>
    <international-brand>
      <name>Prosmon</name>
      <company>Fuji Yakuhin</company>
    </international-brand>
    <international-brand>
      <name>Prostin F2 Alpha</name>
      <company>Pfizer</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Abortifacient Agents</category>
      <mesh-id>D000019</mesh-id>
    </category>
    <category>
      <category>Abortifacient Agents, Nonsteroidal</category>
      <mesh-id>D000020</mesh-id>
    </category>
    <category>
      <category>Angiography</category>
      <mesh-id>D000792</mesh-id>
    </category>
    <category>
      <category>Autacoids</category>
      <mesh-id>D012898</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Eicosanoids</category>
      <mesh-id>D015777</mesh-id>
    </category>
    <category>
      <category>Fatty Acids</category>
      <mesh-id>D005227</mesh-id>
    </category>
    <category>
      <category>Fatty Acids, Unsaturated</category>
      <mesh-id>D005231</mesh-id>
    </category>
    <category>
      <category>Inflammation Mediators</category>
      <mesh-id>D018836</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Prostaglandins</category>
      <mesh-id>D011453</mesh-id>
    </category>
    <category>
      <category>Prostaglandins F</category>
      <mesh-id>D011460</mesh-id>
    </category>
    <category>
      <category>Reproductive Control Agents</category>
      <mesh-id>D012102</mesh-id>
    </category>
    <category>
      <category>Uterotonic agents</category>
      <mesh-id>D010120</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>76:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01160.pdf?1265922743</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00429</drugbank-id>
      <name>Carboprost tromethamine</name>
      <description>Carboprost tromethamine may increase the uterotonic activities of Dinoprost tromethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Licofelone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Polmacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The therapeutic efficacy of Dinoprost tromethamine can be decreased when used in combination with Flurbiprofen axetil.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.11</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.17e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.61</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoic acid; 2-amino-2-(hydroxymethyl)propane-1,3-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>dinoprost tromethamine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>475.616</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>475.314517421</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC(CO)(CO)CO.CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C24H45NO8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>IYGXEHDCSOYNKY-RZHHZEQLSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>97.99</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>100.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>41.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-1.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>0.2 g/mL</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>100-101</value>
      <source>Morozowich, W.; U.S. Patent 3,657,327; April 18,1972; assigned to The Upjohn Company.</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.12</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11487</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31502</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5282415</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46509164</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C12786</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01352</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4445570</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164781385</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000826</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Prostaglandin_F2alpha</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200896</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000610</id>
      <name>Prostaglandin F2-alpha receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16792</ref-id>
            <pubmed-id>8777582</pubmed-id>
            <citation>Sakamoto K, Kamimura M, Kurozumi S, Ito S: Prostaglandin F2 alpha receptor. J Lipid Mediat Cell Signal. 1995 Oct;12(2-3):405-11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P43088" source="Swiss-Prot">
        <name>Prostaglandin F2-alpha receptor</name>
        <general-function>Prostaglandin f receptor activity</general-function>
        <specific-function>Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost.</specific-function>
        <gene-name>PTGFR</gene-name>
        <locus>1p31.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>32-54
70-90
110-131
153-175
199-224
251-267
286-307</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.11</theoretical-pi>
        <molecular-weight>40054.1</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9600</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTGFR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L24470</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>456564</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P43088</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PF2R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PGF receptor</synonym>
          <synonym>Prostanoid FP receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001217|Prostaglandin F2-alpha receptor
MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQ
KSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGL
CPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQ
ASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQG
RSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILD
PWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016151|Prostaglandin F2-alpha receptor (PTGFR)
ATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCTGCAGCTGCGCTTCTTTCAAACACA
ACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTAATCTTCATGACAGTGGGA
ATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCATATCAGAGATTTAGACAG
AAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGTGGCCTGGTAATCACTGATTTCTTTGGC
CATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCTGATAAAGAATGGATCCGC
TTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGCATGGTGTTTTCTGGTCTG
TGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCA
ATATTTCATTCTACGAAAATTACATCCAAACATGTGAAAATGATGTTAAGTGGTGTGTGC
TTGTTTGCTGTTTTCATAGCTTTGCTGCCCATCCTTGGACATCGAGACTATAAAATTCAG
GCGTCGAGGACCTGGTGTTTCTACAACACAGAAGACATCAAAGACTGGGAAGATAGATTT
TATCTTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTTCATTGTTGTGCAAT
GCAATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGTCAGCAGCACAGACAAGGC
AGATCTCATCATTTGGAAATGGTAATCCAGCTCCTGGCGATAATGTGTGTCTCCTGTATT
TGTTGGAGCCCATTTCTGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTG
GAAACCTGTGAAACAACACTTTTTGCTCTCCGAATGGCAACATGGAATCAAATCTTAGAT
CCTTGGGTATATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAGCTTGCCAGT
CAATGCTGTGGAGTGCATGTCATCAGCTTACATATTTGGGAGCTTAGTTCCATTAAAAAT
TCCTTAAAGGTTGCTGCTATTTCTGAGTCACCAGTTGCAGAGAAATCAGCAAGCACCTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin F receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling using intracellular calcium source</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to prostaglandin D stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>parturition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000475</id>
      <name>Prostacyclin receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P43119" source="Swiss-Prot">
        <name>Prostacyclin receptor</name>
        <general-function>Guanyl-nucleotide exchange factor activity</general-function>
        <specific-function>Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.</specific-function>
        <gene-name>PTGIR</gene-name>
        <locus>19q13.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>17-38
52-76
95-115
135-158
182-208
236-260
275-295</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.53</theoretical-pi>
        <molecular-weight>40955.485</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9602</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTGIR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L29016</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>495043</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>345</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>345</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P43119</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PI2R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>PGI receptor</synonym>
          <synonym>PGI2 receptor</synonym>
          <synonym>PRIPR</synonym>
          <synonym>Prostaglandin I2 receptor</synonym>
          <synonym>Prostanoid IP receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010333|Prostacyclin receptor
MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFAVLVTGLAATD
LLGTSFLSPAVFVAYARNSSLLGLARGGPALCDAFAFAMTFFGLASMLILFAMAVERCLA
LSHPYLYAQLDGPRCARLALPAIYAFCVLFCALPLLGLGQHQQYCPGSWCFLRMRWAQPG
GAAFSLAYAGLVALLVAAIFLCNGSVTLSLCRMYRQQKRHQGSLGPRPRTGEDEVDHLIL
LALMTVVMAVCSLPLTIRCFTQAVAPDSSSEMGDLLAFRFYAFNPILDPWVFILFRKAVF
QRLKLWVCCLCLGPAHGDSQTPLSQLASGRRDPRAPSAPVGKEGSCVPLSAWGEGQVEPL
PPTQQSSGSAVGTSSKAEASVACSLC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010334|Prostacyclin receptor (PTGIR)
ATGGCGGATTCGTGCAGGAACCTCACCTACGTGCGGGGCTCGGTGGGGCCGGCCACCAGC
ACCCTGATGTTCGTGGCCGGTGTGGTGGGCAACGGGCTGGCCCTGGGCATCCTGAGCGCA
CGGCGACCGGCGCGCCCCTCGGCCTTCGCGGTGCTGGTGACCGGACTGGCGGCCACCGAC
CTGCTGGGCACCAGCTTCCTGAGCCCGGCCGTGTTCGTGGCCTATGCGCGCAACAGCTCC
CTGCTGGGCCTGGCCCGAGGCGGCCCCGCCCTGTGCGATGCCTTCGCCTTCGCCATGACC
TTCTTCGGCCTGGCGTCCATGCTCATCCTCTTTGCCATGGCCGTGGAGCGCTGCCTGGCG
CTGAGCCACCCCTACCTCTACGCGCAGCTGGACGGGCCCCGCTGCGCCCGCCTGGCGCTG
CCAGCCATCTACGCCTTCTGCGTCCTCTTCTGCGCGCTGCCCCTGCTGGGCCTGGGCCAA
CACCAGCAGTACTGCCCCGGCAGCTGGTGCTTCCTCCGCATGCGCTGGGCCCAGCCGGGC
GGCGCCGCCTTCTCGCTGGCCTACGCCGGCCTGGTGGCCCTGCTGGTGGCTGCCATCTTC
CTCTGCAACGGCTCGGTCACCCTCAGCCTCTGCCGCATGTACCGCCAGCAGAAGCGCCAC
CAGGGCTCTCTGGGTCCACGGCCGCGCACCGGAGAGGACGAGGTGGACCACCTGATCCTG
CTGGCCCTCATGACAGTGGTCATGGCCGTGTGCTCCCTGCCTCTCACGATCCGCTGCTTC
ACCCAGGCTGTCGCCCCTGACAGCAGCAGTGAGATGGGGGACCTCCTTGCCTTCCGCTTC
TACGCCTTCAACCCCATCCTGGACCCCTGGGTCTTCATCCTTTTCCGCAAGGCTGTCTTC
CAGCGACTCAAGCTCTGGGTCTGCTGCCTGTGCCTCGGGCCTGCCCACGGAGACTCGCAG
ACACCCCTTTCCCAGCTCGCCTCAGGGAGGAGGGACCCAAGGGCCCCCTCTGCTCCTGTG
GGAAAGGAGGGGAGCTGCGTGCCTTTGTCGGCTTGGGGCGAGGGGCAGGTGGAGCCCTTG
CCTCCCACACAGCAGTCCAGCGGCAGCGCCGTGGGAACGTCGTCCAAAGCAGAAGCCAGC
GTCGCCTGCTCCCTCTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>guanyl-nucleotide exchange factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of platelet-derived growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of GTPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="3">
      <id>BE0003647</id>
      <name>Solute carrier family 22 member 2</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16031</ref-id>
            <pubmed-id>11907186</pubmed-id>
            <citation>Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15244" source="Swiss-Prot">
        <name>Solute carrier family 22 member 2</name>
        <general-function>Quaternary ammonium group transmembrane transporter activity</general-function>
        <specific-function>Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.</specific-function>
        <gene-name>SLC22A2</gene-name>
        <locus>6q26</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>23-43
151-171
178-198
209-229
239-259
264-284
349-369
376-396
415-435
442-462
465-485
495-515</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.45</theoretical-pi>
        <molecular-weight>62579.99</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10966</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X98333</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2281942</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1020</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15244</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOCT2</synonym>
          <synonym>OCT2</synonym>
          <synonym>Organic cation transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037250|Solute carrier family 22 member 2
MPTTVDDVLEHGGEFHFFQKQMFFLLALLSATFAPIYVGIVFLGFTPDHRCRSPGVAELS
LRCGWSPAEELNYTVPGPGPAGEASPRQCRRYEVDWNQSTFDCVDPLASLDTNRSRLPLG
PCRDGWVYETPGSSIVTEFNLVCANSWMLDLFQSSVNVGFFIGSMSIGYIADRFGRKLCL
LTTVLINAAAGVLMAISPTYTWMLIFRLIQGLVSKAGWLIGYILITEFVGRRYRRTVGIF
YQVAYTVGLLVLAGVAYALPHWRWLQFTVSLPNFFFLLYYWCIPESPRWLISQNKNAEAM
RIIKHIAKKNGKSLPASLQRLRLEEETGKKLNPSFLDLVRTPQIRKHTMILMYNWFTSSV
LYQGLIMHMGLAGDNIYLDFFYSALVEFPAAFMIILTIDRIGRRYPWAASNMVAGAACLA
SVFIPGDLQWLKIIISCLGRMGITMAYEIVCLVNAELYPTFIRNLGVHICSSMCDIGGII
TPFLVYRLTNIWLELPLMVFGVLGLVAGGLVLLLPETKGKALPETIEEAENMQRPRKNKE
KMIYLQVQKLDIPLN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012536|Solute carrier family 22 member 2 (SLC22A2)
ATGCCCACCACCGTGGACGATGTCCTGGAGCATGGAGGGGAGTTTCACTTTTTCCAGAAG
CAAATGTTTTTCCTCTTGGCTCTGCTCTCGGCTACCTTCGCGCCCATCTACGTGGGCATC
GTCTTCCTGGGCTTCACCCCTGACCACCGCTGCCGGAGCCCCGGAGTGGCCGAGCTGAGT
CTGCGCTGCGGCTGGAGTCCTGCAGAGGAACTGAACTACACGGTGCCGGGCCCAGGACCT
GCGGGCGAAGCCTCCCCAAGACAGTGTAGGCGCTACGAGGTGGACTGGAACCAGAGCACC
TTCGACTGCGTGGACCCCCTGGCCAGCCTGGACACCAACAGGAGCCGCCTGCCACTGGGC
CCCTGCCGGGACGGCTGGGTGTACGAGACGCCTGGCTCGTCCATCGTCACCGAGTTTAAC
CTGGTATGTGCCAACTCCTGGATGTTGGACCTATTCCAGTCATCAGTGAATGTAGGATTC
TTTATTGGCTCTATGAGTATCGGCTACATAGCAGACAGGTTTGGCCGTAAGCTCTGCCTC
CTAACTACAGTCCTCATAAATGCTGCAGCTGGAGTTCTCATGGCCATTTCCCCAACCTAT
ACGTGGATGTTAATTTTTCGCTTAATCCAAGGACTGGTCAGCAAAGCAGGCTGGTTAATA
GGCTACATCCTGATTACAGAATTTGTTGGGCGGAGATATCGGAGAACAGTGGGGATTTTT
TACCAAGTTGCCTATACAGTTGGGCTCCTGGTGCTAGCTGGGGTGGCTTACGCACTTCCT
CACTGGAGGTGGTTGCAGTTCACAGTTTCTCTGCCCAACTTCTTCTTCTTGCTCTATTAC
TGGTGCATACCTGAGTCTCCCAGGTGGCTGATCTCCCAGAATAAGAATGCTGAAGCCATG
AGAATCATTAAGCACATCGCAAAGAAAAATGGAAAATCTCTACCCGCCTCCCTTCAGCGC
CTGAGACTTGAAGAGGAAACTGGCAAGAAATTGAACCCTTCATTTCTTGACTTGGTCAGA
ACTCCTCAGATAAGGAAACATACTATGATATTGATGTACAACTGGTTCACGAGCTCTGTG
CTCTACCAGGGCCTCATCATGCACATGGGCCTTGCAGGTGACAATATCTACCTGGATTTC
TTCTACTCTGCCCTGGTTGAATTCCCAGCTGCCTTCATGATCATCCTCACCATCGACCGC
ATCGGACGCCGTTACCCTTGGGCTGCATCAAATATGGTTGCAGGGGCAGCCTGTCTGGCC
TCAGTTTTTATACCTGGTGATCTACAATGGCTAAAAATTATTATCTCATGCTTGGGAAGA
ATGGGGATCACAATGGCCTATGAGATAGTCTGCCTGGTCAATGCTGAGCTGTACCCCACA
TTCATTAGGAATCTTGGCGTCCACATCTGTTCCTCAATGTGTGACATTGGTGGCATCATC
ACGCCATTCCTGGTCTACCGGCTCACTAACATCTGGCTTGAGCTCCCGCTGATGGTTTTC
GGCGTGCTTGGCTTGGTTGCTGGAGGTCTGGTGCTGTTGCTTCCAGAAACTAAAGGGAAA
GCTTTGCCTGAGACCATCGAGGAAGCCGAAAATATGCAAAGACCAAGAAAAAATAAAGAA
AAGATGATTTACCTCCAAGTTCAGAAACTAGACATTCCATTGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>choline transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic cation transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quaternary ammonium group transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ammonium transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>body fluid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>choline transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quaternary ammonium group transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0001066</id>
      <name>Solute carrier family 22 member 6</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16031</ref-id>
            <pubmed-id>11907186</pubmed-id>
            <citation>Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q4U2R8" source="Swiss-Prot">
        <name>Solute carrier family 22 member 6</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-independent uptake of p-aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid (By similarity). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, furosemide, indomethacin, bumetamide, losartan, probenecid, phenol red, urate, and alpha-ketoglutarate.</specific-function>
        <gene-name>SLC22A6</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>10-30
136-156
165-187
191-213
225-245
249-269
338-358
369-389
396-416
426-446
456-475
485-505</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.78</theoretical-pi>
        <molecular-weight>61815.78</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10970</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>hROAT1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF057039</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3831566</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1025</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q4U2R8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT1</synonym>
          <synonym>hPAHT</synonym>
          <synonym>hROAT1</synonym>
          <synonym>OAT1</synonym>
          <synonym>Organic anion transporter 1</synonym>
          <synonym>PAH transporter</synonym>
          <synonym>PAHT</synonym>
          <synonym>Renal organic anion transporter 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037120|Solute carrier family 22 member 6
MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPADANLSKN
GGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGTGATEPCTDGWIYDNSTFPSTI
VTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAA
FAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGYVYSLGQFLLAGV
AYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQRVARINGKREE
GAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFATSFAYYGLVMDL
QGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGICILLNGVIPQDQS
IVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVGSIVSPLVSMTAE
LYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESRWAPTQKEAGIYPRKGKQT
RQQQEHQKYMVPLQASAQEKNGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010747|Solute carrier family 22 member 6 (SLC22A6)
ATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAG
GTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACAACACCCTGCAGAACTTC
ACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC
GGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGC
TTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAGAAGCCAATGGCACAGGG
GCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCATCTACCATC
GTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTG
TACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACCTTGCAGACAGGCTAGGC
CGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC
TTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCT
GGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGCCCATTCACACACGGGCC
TGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG
GCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCC
TTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGCACTCCTCCTCCGGGAGG
CTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA
GGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGC
AAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCCTCCGCCACCTCTTCCTC
TGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG
CAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCT
GCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCCGGCCTGCCCAGATGGCT
GCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC
ATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGC
ATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGCAGACAGGCATGGGAATG
GGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG
CTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTC
ACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACACGGTGCAGGACCTGGAG
AGCAGGTGGGCCCCCACTCAGAAAGAAGCAGGGATATATCCCAGGAAAGGGAAACAGACG
CGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTGCAGGCCTCAGCACAAGAGAAG
AATGGACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chloride ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alpha-ketoglutarate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal tubular secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methotrexate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="5">
      <id>BE0003646</id>
      <name>Solute carrier family 22 member 7</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16031</ref-id>
            <pubmed-id>11907186</pubmed-id>
            <citation>Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y694" source="Swiss-Prot">
        <name>Solute carrier family 22 member 7</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.</specific-function>
        <gene-name>SLC22A7</gene-name>
        <locus>6p21.2-p21.1</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>21-41
146-166
180-200
204-224
234-254
259-279
346-366
376-397
404-423
432-452
466-486
493-513</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.03</theoretical-pi>
        <molecular-weight>60025.025</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10971</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF097518</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5001689</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y694</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT2</synonym>
          <synonym>NLT</synonym>
          <synonym>Novel liver transporter</synonym>
          <synonym>OAT2</synonym>
          <synonym>Organic anion transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007007|Solute carrier family 22 member 7
MGFEELLEQVGGFGPFQLRNVALLALPRVLLPLHFLLPIFLAAVPAHRCALPGAPANFSH
QDVWLEAHLPREPDGTLSSCLRFAYPQALPNTTLGEERQSRGELEDEPATVPCSQGWEYD
HSEFSSTIATESQWDLVCEQKGLNRAASTFFFAGVLVGAVAFGYLSDRFGRRRLLLVAYV
STLVLGLASAASVSYVMFAITRTLTGSALAGFTIIVMPLELEWLDVEHRTVAGVLSSTFW
TGGVMLLALVGYLIRDWRWLLLAVTLPCAPGILSLWWVPESARWLLTQGHVKEAHRYLLH
CARLNGRPVCEDSFSQEAVSKVAAGERVVRRPSYLDLFRTPRLRHISLCCVVVWFGVNFS
YYGLSLDVSGLGLNVYQTQLLFGAVELPSKLLVYLSVRYAGRRLTQAGTLLGTALAFGTR
LLVSSDMKSWSTVLAVMGKAFSEAAFTTAYLFTSELYPTVLRQTGMGLTALVGRLGGSLA
PLAALLDGVWLSLPKLTYGGIALLAAGTALLLPETRQAQLPETIQDVERKSAPTSLQEEE
MPMKQVQN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012535|Solute carrier family 22 member 7 (SLC22A7)
ATGGGCTTTGAGGAGCTGCTGGAGCAGGTGGGCGGCTTTGGGCCCTTCCAACTGCGGAAT
GTGGCACTGCTGGCCCTGCCCCGAGTGCTGCTACCACTGCACTTCCTCCTGCCCATCTTC
CTGGCTGCCGTGCCTGCCCACCGATGTGCCCTGCCGGGTGCCCCTGCCAACTTCAGCCAT
CAGGATGTGTGGCTGGAGGCCCATCTTCCCCGGGAGCCTGATGGCACGCTCAGCTCCTGC
CTCCGCTTTGCCTATCCCCAGGCTCTCCCCAACACCACGTTGGGGGAAGAAAGGCAGAGC
CGTGGGGAGCTGGAGGATGAACCTGCCACAGTGCCCTGCTCTCAGGGCTGGGAGTACGAC
CACTCAGAATTCTCCTCTACCATTGCAACTGAGTGGGATCTGGTGTGTGAGCAGAAAGGT
CTGAACAGAGCTGCGTCCACTTTCTTCTTCGCCGGTGTGCTGGTGGGGGCTGTGGCCTTT
GGATATCTGTCCGACAGGTTTGGGCGGCGGCGTCTGCTGCTGGTAGCCTACGTGAGTACC
CTGGTGCTGGGCCTGGCATCTGCAGCCTCCGTCAGCTATGTAATGTTTGCCATCACCCGC
ACCCTTACTGGCTCAGCCCTGGCTGGTTTTACCATCATCGTGATGCCACTGGAGCTGGAG
TGGCTGGATGTGGAGCACCGCACCGTGGCTGGAGTCCTGAGCAGCACCTTCTGGACAGGG
GGCGTGATGCTGCTGGCACTGGTTGGGTACCTGATACGGGACTGGCGATGGCTTCTGCTA
GCTGTCACCCTGCCTTGTGCCCCAGGCATCCTCAGCCTCTGGTGGGTGCCTGAGTCTGCA
CGCTGGCTTCTGACCCAAGGCCATGTGAAAGAGGCCCACAGGTACTTGCTCCACTGTGCC
AGGCTCAATGGGCGGCCAGTGTGTGAGGACAGCTTCAGCCAGGAGGCTGTGAGCAAAGTG
GCCGCCGGGGAACGGGTGGTCCGAAGACCTTCATACCTAGACCTGTTCCGCACACCACGG
CTCCGACACATCTCACTGTGCTGCGTGGTGGTGTGGTTCGGAGTGAACTTCTCCTATTAC
GGCCTGAGTCTGGATGTGTCGGGGCTGGGGCTGAACGTGTACCAGACACAGCTGTTGTTC
GGGGCTGTGGAACTGCCCTCCAAGCTGCTGGTCTACTTGTCGGTGCGCTACGCAGGACGC
CGCCTCACGCAAGCCGGGACACTGCTGGGCACGGCCCTGGCGTTCGGCACTAGACTGCTA
GTGTCCTCCGATATGAAGTCCTGGAGCACTGTCCTGGCAGTGATGGGGAAAGCTTTTTCT
GAAGCTGCCTTCACCACTGCCTACCTGTTCACTTCAGAGTTGTACCCTACGGTGCTCAGA
CAGACAGGGATGGGGCTGACTGCACTGGTGGGCCGGCTGGGGGGCTCTTTGGCCCCACTG
GCGGCCTTGCTGGATGGAGTGTGGCTGTCACTGCCCAAGCTTACTTATGGGGGGATCGCC
CTGCTGGCTGCCGGCACCGCCCTCCTGCTGCCAGAGACGAGGCAGGCACAGCTGCCAGAG
ACCATCCAGGACGTGGAGAGAAAGAGTGCCCCAACCAGTCTTCAGGAGGAAGAGATGCCC
ATGAAGCAGGTCCAGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07690</identifier>
            <name>MFS_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="6">
      <id>BE0003645</id>
      <name>Solute carrier family 22 member 8</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16031</ref-id>
            <pubmed-id>11907186</pubmed-id>
            <citation>Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q8TCC7" source="Swiss-Prot">
        <name>Solute carrier family 22 member 8</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).</specific-function>
        <gene-name>SLC22A8</gene-name>
        <locus>11q11</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>10-30
124-144
155-175
177-197
213-233
237-257
328-348
355-375
387-407
412-432
472-492</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.05</theoretical-pi>
        <molecular-weight>59855.585</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10972</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF097491</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4378059</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1027</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8TCC7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT3</synonym>
          <synonym>OAT3</synonym>
          <synonym>Organic anion transporter 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007005|Solute carrier family 22 member 8
MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCRPPHNASTGPW
VLPMGPNGKPERCLRFVHPPNASLPNDTQRAMEPCLDGWVYNSTKDSIVTEWDLVCNSNK
LKEMAQSIFMAGILIGGLVLGDLSDRFGRRPILTCSYLLLAASGSGAAFSPTFPIYMVFR
FLCGFGISGITLSTVILNVEWVPTRMRAIMSTALGYCYTFGQFILPGLAYAIPQWRWLQL
TVSIPFFVFFLSSWWTPESIRWLVLSGKSSKALKILRRVAVFNGKKEEGERLSLEELKLN
LQKEISLAKAKYTASDLFRIPMLRRMTFCLSLAWFATGFAYYSLAMGVEEFGVNLYILQI
IFGGVDVPAKFITILSLSYLGRHTTQAAALLLAGGAILALTFVPLDLQTVRTVLAVFGKG
CLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRVGSMVSPLVKITGEVQPFIPNIIYGI
TALLGGSAALFLPETLNQPLPETIEDLENWSLRAKKPKQEPEVEKASQRIPLQPHGPGLG
SS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019450|Solute carrier family 22 member 8 (SLC22A8)
ATGACCTTCTCGGAGATCCTGGACCGTGTGGGAAGCATGGGCCATTTCCAGTTCCTGCAT
GTAGCCATACTGGGCCTCCCGATCCTCAACATGGCCAACCACAACCTGCTGCAGATCTTC
ACAGCCGCCACCCCTGTCCACCACTGTCGCCCGCCCCACAATGCCTCCACAGGGCCTTGG
GTGCTCCCCATGGGCCCAAATGGGAAGCCTGAGAGGTGCCTCCGTTTTGTACATCCGCCC
AATGCCAGCCTGCCCAATGACACCCAGAGGGCCATGGAGCCATGCCTGGATGGCTGGGTC
TACAACAGCACCAAGGACTCCATTGTGACAGAGTGGGACTTGGTGTGCAACTCCAACAAA
CTGAAGGAGATGGCCCAGTCTATCTTCATGGCAGGTATACTGATTGGAGGGCTCGTGCTT
GGAGACCTGTCTGACAGGTTTGGCCGCAGGCCCATCCTGACCTGCAGCTACCTGCTGCTG
GCAGCCAGCGGCTCCGGTGCAGCCTTCAGCCCCACCTTCCCCATCTACATGGTCTTCCGC
TTCCTGTGTGGCTTTGGCATCTCAGGCATTACCCTGAGCACCGTCATCTTGAATGTGGAA
TGGGTGCCTACCCGGATGCGGGCCATCATGTCGACAGCACTCGGGTACTGCTACACCTTT
GGCCAGTTCATTCTGCCCGGCCTGGCCTACGCCATCCCCCAGTGGCGTTGGCTGCAGTTA
ACTGTGTCCATTCCCTTCTTCGTCTTCTTCCTATCATCCTGGTGGACACCAGAGTCCATA
CGCTGGTTGGTCTTGTCTGGAAAGTCCTCGAAGGCCCTGAAGATACTCCGGCGGGTGGCT
GTCTTCAATGGCAAGAAGGAAGAGGGAGAAAGGCTCAGCTTGGAGGAGCTCAAACTCAAC
CTGCAGAAGGAGATCTCCTTGGCCAAGGCCAAGTACACCGCAAGTGACCTGTTCCGGATA
CCCATGCTGCGCCGCATGACCTTCTGTCTTTCCCTGGCCTGGTTTGCTACCGGTTTTGCC
TACTATAGTTTGGCTATGGGTGTGGAAGAATTTGGAGTCAACCTCTACATCCTCCAGATC
ATCTTTGGTGGGGTCGATGTCCCAGCCAAGTTCATCACCATCCTCTCCTTAAGCTACCTG
GGCCGGCATACCACTCAGGCCGCTGCCCTGCTCCTGGCAGGAGGGGCCATCTTGGCTCTC
ACCTTTGTGCCCTTGGACTTGCAGACCGTGAGGACAGTATTGGCTGTGTTTGGGAAGGGA
TGCCTATCCAGCTCCTTCAGCTGCCTCTTCCTCTACACAAGTGAATTATACCCCACAGTC
ATCAGGCAAACAGGTATGGGCGTAAGTAACCTGTGGACCCGCGTGGGAAGCATGGTGTCC
CCGCTGGTGAAAATCACGGGTGAGGTACAGCCCTTCATCCCCAATATCATCTACGGGATC
ACCGCCCTCCTCGGGGGCAGTGCTGCCCTCTTCCTGCCTGAGACCCTGAATCAGCCCTTG
CCAGAGACTATCGAAGACCTGGAAAACTGGTCCCTGCGGGCAAAGAAGCCAAAGCAGGAG
CCAGAGGTGGAAAAGGCCTCCCAGAGGATCCCTCTACAGCCTCACGGACCAGGCCTGGGC
TCCAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="7">
      <id>BE0000879</id>
      <name>Solute carrier family 22 member 11</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16031</ref-id>
            <pubmed-id>11907186</pubmed-id>
            <citation>Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9NSA0" source="Swiss-Prot">
        <name>Solute carrier family 22 member 11</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.</specific-function>
        <gene-name>SLC22A11</gene-name>
        <locus>11q13.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>11-31
143-163
175-195
201-221
232-252
257-277
347-367
379-399
403-423
431-451
464-484
491-511</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.71</theoretical-pi>
        <molecular-weight>59970.945</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:18120</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC22A11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB026116</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7707622</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1030</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NSA0</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22AB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OAT4</synonym>
          <synonym>Organic anion transporter 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001752|Solute carrier family 22 member 11
MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCWTHMLDNGSAV
STNMTPKALLTISIPPGPNQGPHQCRRFRQPQWQLLDPNATATSWSEADTEPCVDGWVYD
RSVFTSTIVAKWDLVCSSQGLKPLSQSIFMSGILVGSFIWGLLSYRFGRKPMLSWCCLQL
AVAGTSTIFAPTFVIYCGLRFVAAFGMAGIFLSSLTLMVEWTTTSRRAVTMTVVGCAFSA
GQAALGGLAFALRDWRTLQLAASVPFFAISLISWWLPESARWLIIKGKPDQALQELRKVA
RINGHKEAKNLTIEVLMSSVKEEVASAKEPRSVLDLFCVPVLRWRSCAMLVVNFSLLISY
YGLVFDLQSLGRDIFLLQALFGAVDFLGRATTALLLSFLGRRTIQAGSQAMAGLAILANM
LVPQDLQTLRVVFAVLGKGCFGISLTCLTIYKAELFPTPVRMTADGILHTVGRLGAMMGP
LILMSRQALPLLPPLLYGVISIASSLVVLFFLPETQGLPLPDTIQDLESQKSTAAQGNRQ
EAVTVESTSL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010620|Solute carrier family 22 member 11 (SLC22A11)
ATGGCGTTCTCGAAGCTCTTGGAGCAAGCCGGAGGCGTGGGCCTCTTCCAGACCCTGCAG
GTGCTCACCTTCATCCTCCCCTGCCTCATGATACCTTCCCAGATGCTCCTGGAGAACTTC
TCAGCCGCCATCCCAGGCCACCGATGCTGGACACACATGCTGGACAATGGCTCTGCGGTT
TCCACAAACATGACCCCCAAGGCCCTTCTGACCATCTCCATCCCGCCAGGCCCCAACCAG
GGGCCCCACCAGTGCCGCCGCTTCCGCCAGCCACAGTGGCAGCTCTTGGACCCCAATGCC
ACGGCCACCAGCTGGAGCGAAGCTGACACGGAGCCGTGTGTGGACGGCTGGGTCTATGAC
CGCAGCGTCTTCACCTCCACCATCGTGGCCAAGTGGGACCTGGTGTGCAGCTCCCAGGGC
TTGAAGCCCCTAAGCCAGTCCATCTTCATGTCCGGGATCCTGGTGGGCTCCTTTATCTGG
GGCCTCCTCTCCTACCGGTTTGGGAGGAAGCCGATGCTGAGCTGGTGCTGCCTGCAGTTG
GCCGTGGCGGGCACCAGCACCATCTTCGCCCCAACATTCGTCATCTACTGCGGCCTGCGG
TTCGTGGCCGCTTTTGGGATGGCCGGCATCTTTCTGAGTTCACTGACACTGATGGTGGAG
TGGACCACGACCAGCAGGAGGGCGGTCACCATGACGGTGGTGGGATGTGCCTTCAGCGCA
GGCCAGGCGGCGCTGGGCGGCCTGGCCTTTGCCCTGCGGGACTGGAGGACTCTCCAGCTG
GCAGCATCAGTGCCCTTCTTTGCCATCTCCCTGATATCCTGGTGGCTGCCAGAATCCGCC
CGGTGGCTGATTATTAAGGGCAAACCAGACCAAGCACTTCAGGAGCTCAGAAAGGTGGCC
AGGATAAATGGCCACAAGGAGGCCAAGAACCTGACCATAGAGGTGCTGATGTCCAGCGTG
AAGGAGGAGGTGGCCTCTGCAAAGGAGCCGCGGTCGGTGCTGGACCTGTTCTGCGTGCCC
GTGCTCCGCTGGAGGAGCTGCGCCATGCTGGTGGTGAAGATGACAGCAGATGGCATTCTG
CATACAGTGGGCCGGCTGGGGGCTATGATGGGTCCCCTGATCCTGATGAGCCGCCAAGCC
CTGCCCCTGCTGCCTCCTCTCCTCTATGGCGTTATCTCCATTGCTTCCAGCCTGGTTGTG
CTGTTCTTCCTCCCGGAGACCCAGGGACTTCCGCTCCCTGACACTATCCAGGACCTGGAG
AGCCAGAAATCAACAGCAGCCCAGGGCAACCGGCAAGAGGCCGTCACTGTGGAAAGTACC
TCGCTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="8">
      <id>BE0003655</id>
      <name>Solute carrier organic anion transporter family member 2A1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16468</ref-id>
            <pubmed-id>8787677</pubmed-id>
            <citation>Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q92959" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 2A1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.</specific-function>
        <gene-name>SLCO2A1</gene-name>
        <locus>3q21</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>33-52
72-92
99-123
168-196
216-236
255-279
322-343
364-387
392-415
519-541
551-576
611-629</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.95</theoretical-pi>
        <molecular-weight>70043.33</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10955</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U70867</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1617590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q92959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO2A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OATP2A1</synonym>
          <synonym>PGT</synonym>
          <synonym>Prostaglandin transporter</synonym>
          <synonym>SLC21A2</synonym>
          <synonym>Solute carrier family 21 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012541|Solute carrier organic anion transporter family member 2A1
MGLLPKLGASQGSDTSTSRAGRCARSVFGNIKVFVLCQGLLQLCQLLYSAYFKSSLTTIE
KRFGLSSSSSGLISSLNEISNAILIIFVSYFGSRVHRPRLIGIGGLFLAAGAFILTLPHF
LSEPYQYTLASTGNNSRLQAELCQKHWQDLPPSKCHSTTQNPQKETSSMWGLMVVAQLLA
GIGTVPIQPFGISYVDDFSEPSNSPLYISILFAISVFGPAFGYLLGSVMLQIFVDYGRVN
TAAVNLVPGDPRWIGAWWLGLLISSALLVLTSFPFFFFPRAMPIGAKRAPATADEARKLE
EAKSRGSLVDFIKRFPCIFLRLLMNSLFVLVVLAQCTFSSVIAGLSTFLNKFLEKQYGTS
AAYANFLIGAVNLPAAALGMLFGGILMKRFVFSLQAIPRIATTIITISMILCVPLFFMGC
STPTVAEVYPPSTSSSIHPQSPACRRDCSCPDSIFHPVCGDNGIEYLSPCHAGCSNINMS
SATSKQLIYLNCSCVTGGSASAKTGSCPVPCAHFLLPAIFLISFVSLIACISHNPLYMMV
LRVVNQEEKSFAIGVQFLLMRLLAWLPSPALYGLTIDHSCIRWNSLCLGRRGACAYYDND
ALRDRYLGLQMGYKALGMLLLCFISWRVKKNKEYNVQKAAGLI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012542|Solute carrier organic anion transporter family member 2A1 (SLCO2A1)
ATGGGGCTCCTGCCCAAGCTCGGCGCGTCCCAGGGCAGCGACACCTCTACTAGCCGAGCC
GGCCGCTGTGCCCGCTCGGTCTTCGGCAACATTAAGGTGTTTGTGCTCTGCCAAGGCCTC
CTGCAGCTCTGCCAACTCCTGTACAGCGCCTACTTCAAGAGCAGCCTCACCACCATTGAG
AAGCGCTTTGGGCTCTCCAGTTCTTCATCGGGTCTCATTTCCAGCTTGAATGAGATCAGC
AATGCCATCCTCATCATCTTTGTCAGCTACTTTGGCAGCCGGGTGCACCGTCCACGTCTG
ATTGGCATCGGAGGTCTCTTCCTGGCTGCAGGTGCCTTCATCCTCACCCTCCCACACTTC
CTCTCCGAGCCCTACCAGTACACCTTGGCCAGCACTGGGAACAACAGCCGCTTGCAGGCC
GAGCTCTGCCAGAAGCATTGGCAGGACCTGCCTCCCAGTAAGTGCCACAGCACCACCCAG
AACCCCCAGAAGGAGACCAGCAGCATGTGGGGCCTGATGGTGGTTGCCCAGCTGCTGGCT
GGCATCGGGACAGTGCCTATTCAGCCATTTGGGATCTCCTATGTGGATGACTTCTCAGAG
CCCAGCAACTCGCCCCTGTACATCTCCATCTTATTTGCCATCTCTGTATTTGGACCGGCT
TTCGGGTACCTGCTGGGCTCTGTCATGCTGCAGATCTTTGTGGACTATGGCAGGGTCAAC
ACAGCTGCAGTTAACTTGGTCCCGGGTGACCCCCGATGGATTGGAGCCTGGTGGCTAGGC
CTGCTCATTTCTTCAGCTTTATTGGTTCTCACCTCTTTCCCCTTTTTTTTCTTCCCTCGA
GCAATGCCCATAGGAGCAAAGAGGGCTCCTGCCACAGCAGATGAAGCAAGGAAGTTGGAG
GAGGCCAAGTCAAGAGGCTCCCTGGTGGATTTCATTAAACGGTTTCCATGCATCTTTCTG
AGGCTCCTGATGAACTCACTCTTCGTCCTGGTGGTCCTGGCCCAGTGCACCTTCTCCTCC
GTCATTGCTGGCCTCTCCACCTTCCTCAACAAGTTCCTGGAGAAGCAGTATGGCACCTCA
GCAGCCTATGCCAACTTCCTCATTGGTGCTGTGAACCTCCCTGCTGCAGCCTTGGGGATG
CTGTTTGGAGGAATCCTCATGAAGCGCTTTGTTTTCTCTCTACAAGCCATTCCCCGCATA
GCTACCACCATCATCACCATCTCCATGATCCTTTGTGTTCCTTTGTTCTTCATGGGATGC
TCCACCCCAACTGTGGCCGAAGTCTACCCCCCTAGCACATCAAGTTCTATACATCCGCAG
TCTCCTGCCTGCCGCAGGGACTGCTCGTGCCCAGATTCTATCTTCCACCCGGTCTGTGGA
GACAATGGAATCGAGTACCTCTCCCCTTGCCATGCCGGCTGCAGCAACATCAACATGAGC
TCTGCAACCTCCAAGCAACTGATCTATTTGAACTGCAGCTGTGTGACCGGGGGATCCGCT
TCAGCAAAGACAGGATCGTGCCCTGTCCCCTGTGCCCACTTCCTGCTCCCGGCCATCTTC
CTCATCTCCTTCGTGTCCCTGATAGCCTGCATCTCCCACAACCCCCTCTACATGATGGTT
CTGCGTGTGGTGAACCAGGAGGAAAAGTCATTTGCCATCGGGGTGCAGTTCTTGTTGATG
CGCTTGCTGGCCTGGCTGCCATCTCCAGCCCTCTATGGCCTCACCATTGACCACTCCTGC
ATCCGGTGGAACTCGCTGTGCTTGGGGAGGCGAGGGGCCTGCGCCTACTATGACAACGAT
GCTCTCCGAGACAGGTACCTGGGCCTGCAGATGGGCTACAAGGCGCTGGGCATGCTGCTG
CTTTGCTTCATCAGCTGGAGGGTGAAGAAGAACAAGGAGTACAACGTGCAGAAGGCGGCA
GGCCTCATCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipid transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="9">
      <id>BE0003661</id>
      <name>Solute carrier organic anion transporter family member 3A1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A16355</ref-id>
            <pubmed-id>14631946</pubmed-id>
            <citation>Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UIG8" source="Swiss-Prot">
        <name>Solute carrier organic anion transporter family member 3A1</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).</specific-function>
        <gene-name>SLCO3A1</gene-name>
        <locus>15q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>41-60
80-100
107-131
175-203
223-243
262-286
345-366
387-410
415-438
540-562
572-597
631-648</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.71</theoretical-pi>
        <molecular-weight>76552.135</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10952</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB031050</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>6683741</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UIG8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SO3A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>OATP-D</synonym>
          <synonym>OATP-RP3</synonym>
          <synonym>OATP3A1</synonym>
          <synonym>OATPD</synonym>
          <synonym>OATPRP3</synonym>
          <synonym>Organic anion transporter polypeptide-related protein 3</synonym>
          <synonym>Organic anion-transporting polypeptide D</synonym>
          <synonym>PGE1 transporter</synonym>
          <synonym>SLC21A11</synonym>
          <synonym>Sodium-independent organic anion transporter D</synonym>
          <synonym>Solute carrier family 21 member 11</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037253|Solute carrier organic anion transporter family member 3A1
MQGKKPGGSSGGGRSGELQGDEAQRNKKKKKKVSCFSNIKIFLVSECALMLAQGTVGAYL
VSVLTTLERRFNLQSADVGVIASSFEIGNLALILFVSYFGARGHRPRLIGCGGIVMALGA
LLSALPEFLTHQYKYEAGEIRWGAEGRDVCAANGSGGDEGPDPDLICRNRTATNMMYLLL
IGAQVLLGIGATPVQPLGVSYIDDHVRRKDSSLYIGILFTMLVFGPACGFILGSFCTKIY
VDAVFIDTSNLDITPDDPRWIGAWWGGFLLCGALLFFSSLLMFGFPQSLPPHSEPAMESE
QAMLSEREYERPKPSNGVLRHPLEPDSSASCFQQLRVIPKVTKHLLSNPVFTCIILAACM
EIAVVAGFAAFLGKYLEQQFNLTTSSANQLLGMTAIPCACLGIFLGGLLVKKLSLSALGA
IRMAMLVNLVSTACYVSFLFLGCDTGPVAGVTVPYGNSTAPGSALDPYSPCNNNCECQTD
SFTPVCGADGITYLSACFAGCNSTNLTGCACLTTVPAENATVVPGKCPSPGCQEAFLTFL
CVMCICSLIGAMAQTPSVIILIRTVSPELKSYALGVLFLLLRLLGFIPPPLIFGAGIDST
CLFWSTFCGEQGACVLYDNVVYRYLYVSIAIALKSFAFILYTTTWQCLRKNYKRYIKNHE
GGLSTSEFFASTLTLDNLGRDPVPANQTHRTKFIYNLEDHEWCENMESVL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017177|Solute carrier organic anion transporter family member 3A1 (SLCO3A1)
ATGCAGGGGAAGAAGCCGGGCGGTTCGTCGGGCGGCGGCCGGAGCGGCGAGCTGCAGGGG
GACGAGGCGCAGAGGAACAAGAAAAAGAAAAAGAAGGTGTCCTGCTTTTCCAACATCAAG
ATCTTCCTGGTGTCCGAGTGCGCCCTGATGCTGGCGCAGGGCACGGTGGGCGCCTACCTG
GTGAGCGTCCTGACCACCCTGGAGCGTAGGTTCAACCTGCAGAGCGCTGACGTGGGTGTG
ATCGCTAGCAGCTTCGAGATCGGGAACCTGGCGCTCATCCTCTTCGTGAGCTACTTCGGG
GCACGCGGGCACCGGCCGCGCCTGATCGGCTGCGGCGGCATCGTCATGGCGCTGGGCGCG
CTGCTGTCGGCGCTGCCCGAGTTCCTGACCCACCAGTACAAGTACGAGGCGGGCGAGATC
CGCTGGGGCGCCGAGGGCCGCGACGTCTGCGCAGCCAACGGCTCGGGCGGCGACGAGGGG
CCCGACCCCGACCTCATCTGCCGCAACCGGACGGCTACCAACATGATGTACTTGCTGCTC
ATTGGGGCCCAGGTGCTCCTGGGCATCGGTGCTACCCCTGTGCAGCCCCTGGGCGTCTCC
TACATCGACGACCACGTGCGGAGGAAGGACTCCTCGCTCTATATAGGAATCCTGTTCACG
ATGCTGGTATTTGGACCAGCCTGCGGGTTTATCCTGGGCTCTTTCTGTACCAAAATCTAC
GTGGATGCGGTCTTCATTGACACAAGTAACCTGGACATCACTCCGGACGACCCCCGCTGG
ATCGGAGCCTGGTGGGGTGGCTTTCTGCTCTGCGGTGCCTTACTCTTCTTCTCTTCCCTC
TTGATGTTTGGGTTTCCACAGTCCCTGCCCCCGCACTCAGAGCCCGCCATGGAAAGCGAG
CAGGCCATGCTCTCCGAAAGAGAATACGAGAGACCCAAGCCCAGCAACGGGGTCCTGAGG
CACCCCCTGGAGCCAGACAGCAGTGCCTCCTGTTTCCAGCAGCTGAGAGTGATCCCGAAG
GTCACCAAGCACCTGCTCTCAAACCCTGTGTTCACCTGCATCATCCTGGCCGCCTGCATG
GAGATTGCAGTGGTGGCTGGCTTCGCTGCCTTTTTGGGGAAGTACCTGGAGCAGCAGTTT
AACCTCACCACCTCTTCTGCCAACCAGCTGCTTGGGATGACTGCGATCCCGTGTGCTTGT
CTGGGTATCTTCCTGGGAGGTCTTTTGGTGAAGAAGCTCAGCCTGTCTGCCCTGGGGGCC
ATTCGGATGGCCATGCTCGTCAACCTGGTGTCCACTGCTTGCTACGTCTCCTTCCTCTTC
CTGGGCTGCGACACTGGCCCTGTGGCTGGGGTTACTGTTCCCTATGGAAACAGCACAGCA
CCTGGCTCAGCCCTGGACCCCTACTCGCCCTGCAATAATAACTGTGAATGCCAAACCGAT
TCCTTCACTCCAGTGTGTGGGGCAGATGGCATCACCTACCTGTCTGCCTGCTTTGCTGGC
TGCAACAGCACGAATCTCACGGGCTGTGCGTGCCTCACCACCGTCCCTGCTGAGAACGCA
ACCGTGGTTCCTGGAAAATGCCCCAGTCCTGGGTGCCAAGAGGCCTTCCTCACTTTCCTC
TGTGTGATGTGTATCTGCAGCCTGATCGGTGCCATGGCACAGACACCCTCAGTCATCATC
CTCATCAGGACAGTCAGCCCTGAACTCAAGTCTTACGCTTTGGGAGTTCTTTTTCTCCTC
CTTCGTTTGTTGGGCTTCATCCCTCCACCCCTCATCTTCGGGGCTGGCATCGACTCCACC
TGCCTGTTCTGGAGCACGTTCTGTGGGGAGCAAGGCGCCTGCGTCCTCTACGACAATGTG
GTCTACCGATACCTGTATGTCAGCATCGCCATCGCGCTCAAATCCTTCGCCTTCATCCTG
TACACCACCACGTGGCAGTGCCTGAGGAAAAACTATAAACGCTACATCAAAAACCACGAG
GGCGGGCTGAGCACCAGCACAGAGTACCAAGACATTGAGACTGAGAAAACCTGCCCCGAA
TCACATTCACCTTCAGAAGACTCCTTTGTGAGAAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07648</identifier>
            <name>Kazal_2</name>
          </pfam>
          <pfam>
            <identifier>PF03137</identifier>
            <name>OATP</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>